Abstract. Hepatitis C virus (HCV) infection has become a severe health problem worldwide. The viral proteins are believed to be among the most important factors that contribute to HCV mediated pathogenesis. Accumulated evidence demonstrating that HCV non-structural protein 3 (NS3) possesses oncogenic potential, and is involved in the regulation of cell proliferation has been documented. In this study, we emphasized the effect of HCV NS3 protein on cell proliferation in the immortally normal hepatocyte QSG7701 cells. The cell line transfected with plasmid expressing NS3 protein showed enhanced cell growth, extracellular signal-related kinase (ERK) activation, DNA binding activities of transcription factors of activator protein 1 (AP-1) and NF-κB, and cyclin D1 over-expression, but without activation of Jun amino-terminal kinase or p38. Pre-treatment of NS3 protein expressing cells with ERK inhibitor, PD98059, blocked the activation of AP-1 and NF-κB, and inhibited cyclin D1 expression and cell proliferation. The results suggest that NS3-mediated cell growth occurs through activation of ERK/AP-1 and NF-κB/cyclin D1 cascades.

Introduction

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV). The disease affects ~200 million people worldwide (1), HCV infections often progress to persistent infection and advance to severe liver injury such as chronic hepatitis C, liver cirrhosis and primary hepatocyte carcinoma (HCC) when the immune system of acute HCV-infected patients fails to clear the virus or responds poorly to antiviral therapy (2).

HCV is an enveloped, single-stranded positive-sense RNA virus that belongs to the family Flaviviridae. The 9.6-kb viral genome encodes a precursor polyprotein of ~3,010 amino acids, which is cleaved by both the cellular and viral proteases into at least 4 structural proteins (core, E1, E2 and p7) and 6 non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).

Non-structural protein 3 (NS3) possesses serine protease activity, which is important for viral protein processing (3), and nucleotide triphosphatase-RNA helicase activity, which is essential for virus replication (4-7). Besides its pivotal role in viral protein processing and virus replication, the HCV NS3 protein was reported to be involved in malignant transformation of NIH3T3 cells (8). Our previous study also showed the oncogenic potential of HCV NS3 N terminal protein (9).

In our previous study, we found that HCV NS3 N terminal protein can activate the mitogen-activated (MAPK) signaling pathway extracellular signal-related kinase (ERK) in the immortal normal hepatocyte QSG7701 cells (10), which might have been involved in the stimulation of cell growth (11,12). The disturbance of cell proliferation is closely associated with carcinogenesis. However, the refined mechanisms of this regulation remain to be determined. HCV NS3 N terminal protein and the whole HCV NS3 protein might possess a different biological manner. To address this problem, the normal human hepatocyte cell line QSG7701 was used in this study. The results showed that the cell transfected the whole HCV NS3 protein, promoting cell growth and activated ERK/activator protein 1 (AP-1) and NF-κB/cyclin D1 cascades, suggesting that the activation of ERK/AP-1 and NF-κB/cyclin D1 cascades is essential for the stimulation of HCV NS3 protein-mediated cell growth in QSG7701 cell line.

Materials and methods

Cell culture. The human hepatocyte cell line QSG7701 was obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences (Shanghai,
Clones were obtained from the plasmid pcDNA3.1-NS3 transfection and transferred into 24-well dishes. Ten positive colonies resistant to G418 were isolated with cloning cylinders and transferred into 24-well dishes. The selection process lasted 31 days to allow colony formation.

Transfection and selection of cell strains with stable expression of HCV NS3 protein. DMEM culture medium with 10% fetal calf serum was used to culture QSG7701 cells in 12-well cell culture plates until cells covered 90-95% of the area. Serum-free DMEM was used for culture overnight. Transfection of cell lines was conducted with a Lipofectamine 2000 manufacturer, liposome and plasmid pcDNA3.1-NS3 were mixed and added to each well. pcDNA3.1 empty vector transfection group and blank control group (only liposome was mixed and added to each well). pcDNA3.1-NS3 plasmid.

Plasmid construction. The HCV cDNA p90HCVconFLongpU (13) was kindly provided by Professor Charles M. Rice (Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO). The non-expressive plasmid pcDNA3.1(+) was purchased from Invitrogen (Groningen, The Netherlands). The sense primer 5’-CCC AAG CTT ATG GCC CCC ATC ACG GCC GAC CTC CAG GTC GG-3’ contains a start codon (bold) and a HindIII restriction site (underlined), and the anti-sense primer 5’-CG GGA TCC ATG GCG CCC ATC ACG GCG TAC G-3’ includes a stop codon (bold) and a BamHI restriction site (underlined). These primers were used to amplify the cDNA encoding regions of HCV NS3 (nt 3340-5244, gene bank #AF009606). The amplified PCR products were digested by HindIII and BamHI, and then cloned into pcDNA3.1(+) to generate pcDNA3.1-NS3 plasmid.

Experimental groups. Experimental groups include 3 clones expressing HCV NS3 protein, 1 clone transfected with empty plasmid pcDNA3.1 and QSG7701 parental cells. Group 1-3, QSG7701 transfected with plasmid pcDNA3.1-NS3 (QSG7701/NS3-1, 2, 3); 4, QSG7701 transfected with empty plasmid pcDNA3.1 (QSG7701/pDNA3.1); 5, QSG7701 parental cells.

Western blotting. Western blot analysis was performed with collected cell lysate as described before (12). Collected samples were mixed with standard 2x SDS reducing gel-loading buffer containing 5% β-mercaptoethanol. Samples were boiled for 10 min before loaded onto 4-15% SDS-PAGE gels. After electrophoresis, proteins were transferred onto an Immobilon-PVDF membrane (Millipore Corp., Bedford, MA) in 25 mM Tris, 192 mM glycine, and 15% methanol. The membranes were blocked in 5% non-fat milk (Bio-Rad) in PBS for 2 h and then probed with antibodies. Antibodies were used at the following dilutions and obtained from the indicated sources, anti-HCV NS3 antibody diluted 1:1,000 (Santa Cruz Biotechnology, Santa Cruz, USA); anti-p44/42 MAPK antibody diluted 1:1,000 (#9102, Cell Signaling); anti-phospho-p44/42 MAPK antibody diluted 1:1,000 (#9101, Cell Signaling), anti-p38 MAPK antibody diluted 1:1,000 (Sc-7972, Santa Cruz Biotechnologies), and anti-phospho-p38 MAPK diluted 1:1,000 (Sc-7973, Santa Cruz Biotechnologies), anti-SAPK/Jun amino-terminal kinase (JNK) MAPK antibody diluted 1:1,000 (#9252, Cell Signaling); anti-phospho-SAPK/JNK MAPK antibody diluted 1:1,000 (#9251, Cell Signaling); anti-cyclin D1 antibody diluted 1:1,000 (NewMarker). Anti-β-actin antibody (1:2,000, Santa Cruz Biotechnology) was used as a loading control. Horseradish peroxidase conjugated goat anti-mouse or goat anti-rabbit IgG (H+L) (Bio-Rad Laboratories, Melville, NY), diluted 1:5,000, was used as a secondary antibody. Visualization of immunoreactive proteins was achieved by using the ECL Western blotting detection reagents (Amershams Corp., Heights, IL) and the membrane was exposed to a Kodak X-Omat AR film. Molecular weights of the immunoreactive proteins were determined using two different sets of protein marker ladders. All experiments were performed at least three times.
4-8˚C. Briefly, cells were washed with ice-cold PBS buffer and harvested by the addition of 500 μl of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) containing protease inhibitor and incubated on ice for 10 min. The supernatant was resuspended after centrifugation at 14,000 rpm for 3 min. The pellet was resuspended in 50 μl of buffer C (20 mM HEPES, pH 7.9, 0.42 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) containing protease inhibitor and incubated for 20 min at 4˚C and then centrifuged at 14,000 rpm for 3 min. The supernatant containing nuclear protein was quantified by BCA protein assay kit and stored at -70˚C.

Electrophoretic mobility shift assays (EMSA). The operating procedures of EMSA were according to the LightShift Chemiluminescent EMSA Kit (#20148, Pierce Biotechnologies) protocol. Specific oligonucleotides for binding of AP-1 (S, 5' - CGC TTG ATG AGT CAG CCG GAA - 3'; A, 3' - AGT TGA GGG GAC TTT CCC AGG C - 5'), and NF-κB (S, 5' - GAC TAC TCA GTC GGC CTT - 5'), and NF-κB (A, 3' - TCA ACT CCC CTG AAA GGG TCC G - 5') were prepared by end labeling of the 5'-terminus with Biotin (synthesized by Biosia Biotech, Shanghai, China). Three independent experiments were performed.

MTT cell proliferation assay. MTT assay was used to analyse cell proliferation in the sample. Cells were seeded on 96-well plates at a predetermined optimal cell density to ensure exponential growth in the duration of the assay. After incubation for 72 h, 20 μl MTT (5 g/l) was added to each well and the plate was incubated at 37˚C for 4 h. Then all culture medium supernatant was removed from wells and replaced with 100 μl DMSO. Plates were shaken for 15 min. All formation production induced by MTT was dissolved. Then, a microplate reader at 492 nm measured the absorbance in each well. The inhibition of cell growth was calculated by the equation, growth inhibitory rate = (1 - A492 treated/A492 control) x 100%. The experiment was repeated three times.

Flow cytometry. Cells were seeded at a density of 2x10^5 cells per 100-mm culture dish and covered with 5 ml of PrEGM. After 24 h, the medium was replaced. Flow cytometry was used to analyse the cell cycle in the sample. Cells were seeded at a density of 2x10^5 cells per 100-mm culture dish to ensure exponential growth for the duration of the assay. After incubation for 72 h, cells were washed in PBS 3 times and collected. For flow cytometry analysis, samples were centrifuged for 5 min at 200 x g, washed with 5 ml of PBS and then resuspended in 1 ml of freshly prepared staining solution [propidium iodide (1 g/l) diluted 1:50 in 0.1% (v/v) Triton X-100 in PBS containing RNase A (0.2 g/l)]. The analysis was performed after 30 min of incubation at room temperature. Cells (10,000) were analyzed for cell cycle distribution using a Becton Dickinson FACScan flow cytometer equipped with a 488-nm argon laser and CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA). Cell cycle distribution was analyzed by Mod-fit software (Verity Software House, Topsham, ME). The experiment was repeated three times.

Statistical analysis. Data were analyzed using the Statistical Package for Social Science (SPSS Release 11.5; SPSS Inc., Chicago, IL, USA). A P-value <0.05 or <0.01 was considered significant. Results are expressed as the mean ± SD of data obtained in triplicate.

Results

HCV NS3 protein expression in QSG7701 cells. HCV NS3 protein expression was detected in QSG7701 cells transfected with pcDNA3.1-NS3 by RT-PCR and Western blotting. All of the three positive clones had NS3 protein expression. However NS3 did not express in pcDNA3.1 transfected and nontransfected cells (Fig. 1A and B).

Effects of HCV NS3 protein expression on cell growth. MTT was repeated 3 times and used to detect the proliferation ability of QSG7701/NS3-1, 2, 3, QSG7701/pcDNA3.1 and QSG7701 cells, respectively. The results show that proliferation ability of QSG7701/NS3 was much higher than that of QSG7701/pcDNA3.1 and QSG7701 cells (Table I). Cell distribution of the cell cycle was detected by FCM. Comparing to QSG7701/pcDNA3.1 and QSG7701 cells, the pcDNA3.1-NS3 transfected cells had G1 phase cells decreased and S phase cells increased (Table II), suggesting the QSG7701/NS3 cells have advantage in proliferation.

Effect of HCV NS3 protein on phosphorylation of MAPK. Three groups of MAPK, extracellular signal-related kinase (ERK)–1/2 (P44/42MAPK), JNK, p38 proteins, are closely related to cell growth in mammalian cells. All of these kinases are activated by phosphorylation. As shown in Fig. 2, Western blot analysis demonstrated that HCV NS3 protein does not alter the expression of JNK, p38, or ERK in QSG7701 cell

Table I. MTT analysis of cell proliferation.

<table>
<thead>
<tr>
<th>Groups</th>
<th>OD value ±s</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, QSG7701/NS3-1</td>
<td>1.5063±0.06329</td>
</tr>
<tr>
<td>2, QSG7701/NS3-2</td>
<td>1.3605±0.00493</td>
</tr>
<tr>
<td>3, QSG7701/NS3-3</td>
<td>1.3670±0.07236</td>
</tr>
<tr>
<td>4, QSG7701/pcDNA3.1</td>
<td>1.1353±0.05302</td>
</tr>
<tr>
<td>5, QSG7701</td>
<td>1.1748±0.06259</td>
</tr>
</tbody>
</table>

P<0.05
clones. However, the phosphorylation level of ERK was higher in QSG7701/NS3 cells than in QSG7701/pcDNA3.1 or QSG7701 cells. In contrast, there was no change in the phosphorylation of p38 or JNK. These observations suggest that HCV NS3 expression has no effect on the basal expression of MAPK, but mediates the activation of ERK through inducing phosphorylation, which may be important for the stimulation of HCV NS3 protein-mediated cell growth.

**Table II. FCM analysis of cell cycle.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>G1 (%)</th>
<th>S (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, QSG7701/NS3-1</td>
<td>67.0</td>
<td>24.8</td>
</tr>
<tr>
<td>2, QSG7701/NS3-2</td>
<td>70.5</td>
<td>21.4</td>
</tr>
<tr>
<td>3, QSG7701/NS3-3</td>
<td>67.1</td>
<td>21.8</td>
</tr>
<tr>
<td>4, QSG7701/pcDNA3.1</td>
<td>77.0</td>
<td>13.9</td>
</tr>
<tr>
<td>5, QSG7701</td>
<td>81.4</td>
<td>11.5</td>
</tr>
</tbody>
</table>

P<0.01

**Detecting the DNA binding activity of AP-1 and NF-κB, and the expression of cyclin D1 protein.** As an important downstream effector of ERK, AP-1 regulates directly the expression of cyclin D1 to affect the progress of the cell cycle. Signal transcription factor NF-κB is an important modulator of cell proliferation. To elucidate further the mechanism of the HCV NS3 protein-mediated cell growth, we detected the DNA binding activity of AP-1 and NF-κB, and the expression of cyclin D1 protein. EMSA analysis demonstrated that the DNA binding activity of AP-1 (Fig. 3A) and NF-κB (Fig. 3B) in QSG7701/NS3 cells was much higher than that in QSG7701/pcDNA3.1 and QSG7701 cells. Meanwhile, the results of Western blotting showed that cyclin D1 (Fig. 3C) protein expression was also up-regulated in QSG7701/NS3 cells. These results suggest the stimulation of HCV NS3 protein-mediated cell growth may employ the activation of AP-1 and NF-κB/cyclin D1.

**ERK inhibitor, PD98059, prevents activation of AP-1 and NF-κB, and the expression of cyclin D1 protein, in HCV NS3-expressing cells.** ERK inhibitor, PD98059, specifically inhibits the activation of ERK (Fig. 4A). In order to determine whether the activation of ERK by HCV NS3 protein, is directly associated with the induced cell growth of QSG7701, we used PD98059 to block ERK activity and investigated the effect on HCV NS3-induced cell growth. In the inhibition experiments, one of the three QSG7701/NS3 cell clones was taken randomly as an experimental cell clone, and cells were pre-treated with PD98059 at 0, 30, 50 and 100 μM for 48 h before the evaluation of ERK activation. Results of EMSA revealed that PD98059 inhibits HCV NS3-induced activation of AP-1 (Fig. 4B) and NF-κB (Fig. 4C), and Western blotting showed that HCV NS3-induced expression of cyclin D1 was decreased (Fig. 4D). MTT (Fig. 4E) and FCM (Table III) analysis illustrated that PD98059 can down-regulate HCV NS3-induced proliferation. These results suggest that the activation of AP-1 and NF-κB/cyclin D1, which were induced to express HCV NS3 protein, occurs as a direct consequence of HCV-induced activation of ERK. In addition, the ability of PD98059 to inhibit the HCV NS3 protein-mediated cell growth suggests that the activation of the ERK signaling pathway is essential for stimulation of HCV NS3 protein-mediated proliferative activity.
The oncogenic potential of HCV NS3 protein has been well documented (8,9,14,15). The disturbance of cell proliferation is closely associated with hepatocarcinogenesis. So this work emphasized the effect of HCV NS3 protein on cell proliferation. The proliferative advantage appears in the immortal normal hepatocyte QSG7701 cells expressing stably HCV NS3 protein, suggesting the potential role of HCV NS3 protein in the promotion of cell growth. The results provide an insight into the mechanisms of how the HCV NS3 protein mediates its oncogenic activity in infected cells and are supported by previous findings (14,16,17). In addition, we also show the HCV NS3-stimulated cell growth is ERK/AP-1 cascade dependent.

Cell proliferation and apoptosis are regulated accurately by signaling cascades (18). Specifically the MAP kinase signaling cascade plays a key role in hepatocarcinogenesis (19,20). Mammals express mainly three distinctly regulated groups of MAPK, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK) and p38 proteins. ERK1/2 cascade is mainly correlated to cell proliferation and survival. Raf-1-mediated cell proliferation is dependent on the activation of ERK, which progresses cells from G1 phase to S phase (21). The suppression of ERK activation in fibroblasts by antisense RNA or deficient mutants could inhibit the proliferative response (22). Moreover, ERK plays a central role in the regulation of the level of p27kip1 protein, which can bind and inhibit cyclin E-Cdk2, block the G1/S transition (23). ERK can also affect the progression of the cell cycle by phosphorylation and degradation of the p27kip1 protein (24). All the information suggests that ERK is associated closely with the progression of the cell cycle. We found HCV NS3 protein induces activation of ERK signaling pathway together with the promotion of cell growth. It suggests a potential role for this pathway in the modulation of HCV NS3 protein-mediated oncogenic activity in host cells. Therefore, the ability of the ERK inhibitor to abrogate HCV NS3-induced cell growth supports that ERK activation is an essential component in the HCV NS3-stimulated cell growth.

As an important downstream effector of ERK, AP-1 regulates directly the expression of cyclin D1 to modulate the progress of the cell cycle (25,26). ERK can stimulate the induction of cyclin D1 by enhancing AP-1 activity indirectly, resulting in cell proliferation (27). Silencing of AP-1 by specific antisense oligonucleotides inhibited S phase entry and cell proliferation (28-30). Our results demonstrated the activation of ERK, AP-1 and its substrates cyclin D1 by HCV NS3 protein and delineated the importance of the ERK/AP-1/cyclin D1 cascade for modulation of HCV NS3 protein-mediated cell growth. Thus, HCV NS3 protein could promote cellular proliferation for maintenance of replication and survival (31,32) by this cascade and contribute to hepatocarcinogenesis.

NF-κB is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in the development of cancer. Major carcinogens and oncogenic viruses induce NF-κB activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-κB activation as an important common pathway in most forms of cancer. NF-κB target genes promote tumor cell proliferation, survival,
migration, inflammation, and angiogenesis (33). Guttridge et al demonstrated NF-κB regulation of cyclin D1 occurs at the transcriptional level and is mediated by direct binding of NF-κB to multiple sites in the cyclin D1 promoter, which induces cyclin D1 expression and promotes G1-to-S progression (34). Moreover, the ERK substrate p90-RSK can phosphorylate IkB and induce its degradation (35), and ERK can down-regulate the expression of PAR-4, an inhibitor of proliferation (34). Moreover, the ERK substrate p90-RSK can inhibit activation of NF-κB (36,37), suggesting NF-κB activation may be regulated by ERK. In this work, ERK inhibitor, PD98059, inhibits activation of NF-κB in the HCV NS3 expressed cell. This result indicates that, in addition to the ERK/AP-1/cyclin D1 cascade, HCV NS3 protein-mediated cell growth also involves the ERK/NF-κB/cyclin D1 cascade as well.

HCV NS3 protein mediated cell growth in liver and in non-liver cell lines such as HepG2 and Hela, which have been demonstrated to involve the activation of JNK/AP-1 signaling pathway (16). However, different cell lines and methods were used in these two studies, which might contribute to the variation in outcomes (38,39). Although different signal pathways may be involved, the potential role of HCV NS3 protein in the promotion of cell growth is consistent between our study and others.

In summary, our data demonstrate HCV NS3 protein can promote cell growth and contribute to hepatocarcinogenesis by the activation of ERK/AP-1 and NF-κB/cyclin D1 cascades.

Acknowledgements

We thank Professor Charles M. Rice for providing HCV cDNA p90HCVconFLonGP. This study was supported by research grants from the National Natural Science Foundation of China (No. 30270601 and No. 30671846).

References


